Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

Inclusion Criteria: * Patients with a diagnosis of neovascular glaucoma (Stage I-II) * Individuals who are ages 21-90 years old; male or female of any race * Presence of neovascularization of the iris and/or angle * At least 90 degrees of "unzipped" anterior chamber angle as noted by gonioscopy. (a "zipped angle is the term used for a drainage angle that is slowly closing due to scar tissue from the neovascularization process) * Visual acuity of light perception or better in the study eye * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Use of intravitreal anti-VEGF agents in the study eye in the past 3 months. * Full PRP in the study eye * Prior vitrectomy in the study eye * Prior trabeculectomy or other filtration surgery in the study eye * Active ocular or periocular infection in the study eye * Ocular conditions (Cataract or vitreous hemorrhage) that might require surgery in next 12 months * Allergy to fluorescein dye * Any past use of systemic anti-VEGF medication * Myocardial infarction within 6 months prior to study enrollment * Stroke within 6 months prior to study enrollment * Pregnant or breast-feeding women * Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study